← Back

Wuxi Commercial Mansion Grand Orient Co Ltd

Wuxi Commercial Mansion Grand Orient Co., Ltd. operates department store retail and healthcare businesses in China. It retails department store merchandise and household appliances, produces and sells food, and provides health services. The company also sells food, gold, and jewelry; purchases agricultural and sideline products; retails meat, eggs, aquatic products, and pre-cleaned vegetables; and offers catering, freight station operations, general road freight transportation, repair and modification of gold jewelry, installation and repair of household appliances, clothing and eyeglasses processing, commodity packaging, rental of self-owned premises, economic information consulting, domestic advertising design, production and publication, network technology consulting and transfer, computer software development and sales, beauty services, parking services, optometry and eyeglass fitting, photography, watch repair, retail of books, newspapers, cigarettes, and cigars, and entertainment venue operations. Founded in 1969, it is headquartered in Wuxi, China.

Country
Price · split & dividend adjusted
News & notes moving 600327.CG
600327.CG

Great Eastern's 2026 interim net profit falls 58.17% year-on-year

Great Eastern released its 2026 interim report. Total operating revenue was 1.312 billion yuan, down 27.28% from the same period last year. Net profit attributable to the parent company was 24.6927 million yuan, down 58.17% year-on-year. Net cash inflow from operating activities was 165 million yuan. The asset-liability ratio was 31.90%, gross margin was 17.66%, return on equity was 0.88%, and diluted earnings per share was 0.03 yuan. The company had 53,100 shareholders, and the top ten shareholders held 48.50% of total share capital.
Jiemian·24dRead more →
600327.CG

Dongfang's Controlling Shareholder Pledges 24.02 Million Shares, Cumulative Pledge Exceeds 70% of Holdings

Dongfang announced that its controlling shareholder, Jiangsu Wuxi Commercial Building Group, has pledged 24.02 million shares, representing 6.07% of its holdings and 2.71% of the company's total share capital. As of the disclosure date, the group's cumulative pledged shares have reached 292 million shares, accounting for 73.83% of its holdings and 33.00% of the company's total share capital. In the first quarter of 2026, the company achieved revenue of 709 million yuan and a net profit attributable to the parent of 18.14 million yuan.
财中社·54dRead more →
600327.CG3

Dongfang plans to buy back shares for 50 million to 100 million yuan

Dongfang announced plans to repurchase shares through centralized bidding, with a total repurchase amount of no less than 50 million yuan and no more than 100 million yuan, and a maximum repurchase price of 5.17 yuan per share. It is expected to repurchase between 9.67 million and 19.34 million shares, accounting for 1.09% to 2.19% of the total share capital. The implementation period for the repurchase plan is three months after approval by the board of directors, and the repurchased shares will be used to maintain company value and shareholder interests. In the first quarter of 2026, Dongfang achieved revenue of 709 million yuan and net profit attributable to the parent company of 18.14 million yuan.
财中社·64dRead more →
600327.CG

Dongfang Group expects first-half 2026 net profit attributable to parent to fall 49.18% to 66.12% year-on-year

Dongfang Group disclosed a profit forecast, expecting net profit attributable to the parent for the first half of 2026 to be between 20 million yuan and 30 million yuan, a year-on-year decline of 49.18% to 66.12%. Net profit after deducting non-recurring items is expected to be between 18.897 million yuan and 28.897 million yuan, a year-on-year decline of 31.43% to 55.16%. The company stated that the decline in performance was mainly due to the department store retail business being affected by weak consumer markets and intensified industry competition, with revenue and gross profit falling year-on-year; the medical pediatrics business being affected by price declines after centralized procurement of major drugs, with profit decreasing year-on-year; and investment income from associated enterprises falling year-on-year.
中国证券报·67dRead more →